Durable CD8-mediated remission after brief anti-HIV-1 antibody treatment requires FcγR engagement
Despite highly efficacious antiretroviral therapy (ART), durable ART-free remission remains a central objective of HIV-1 cure strategies. The randomized, placebo-controlled RIO trial recently demonstrated that long-acting broadly neutralizing anti-HIV-1 antibodies (bNAbs) can sustain prolonged virologic control after ART interruption, including control that persisted beyond the period of therapeutically relevant antibody concentrations, providing clinical evidence consistent with host-mediated suppression. However, the mechanisms underlying these "vaccinal" effects remain unresolved. Here, we establish Fcγ receptor (FcγR) engagement as an essential driver of multiyear remission after bNAb therapy in simian-human immunodeficiency virus (SHIV)-infected macaques. Brief therapy during acute infection with Fc domain variants of the bNAb 3BNC117, matched for antigen binding, neutralizing activity, and pharmacokinetics but differing in FcγR engagement, produced comparable early virologic control yet profoundly divergent long-term outcomes. Sustained CD8 T cell-dependent suppression lasting nearly 300 wk developed in every evaluable animal receiving the FcγR-engaging variant but arose in only one of eight recipients of the FcγR-null variant. FcγR-driven immunomodulation imprinted a CD8 T cell response characterized by enhanced antigen-specific effector function, early clonal focusing with sustained clonotype persistence, and distinct cellular-state transcriptional signatures. Our findings identify the Fc-FcγR axis as a critical determinant of the reliable induction of durable remission and provide a mechanistic framework for developing Fc-engineered bNAbs designed to enhance vaccinal immunity and advance antibody-based strategies with the potential to achieve functional cure.
Authors
- Jeffrey V. Ravetch (ORCID: https://orcid.org/0000-0003-2024-9041)
- Daniel C. Rogan (ORCID: https://orcid.org/0000-0002-9766-4166)
- Stylianos Bournazos (ORCID: https://orcid.org/0000-0001-5466-5620)
- Reza Sadjadpour (ORCID: https://orcid.org/0000-0003-3605-5196)
- Mark Connors (ORCID: https://orcid.org/0000-0002-2108-8705)
- Yoshiaki Nishimura (ORCID: https://orcid.org/0000-0003-1347-2368)
- Eric Jesteadt (ORCID: https://orcid.org/0000-0002-7501-4541)
- Paulina A. Przygonska (ORCID: https://orcid.org/0009-0009-4446-5452)
- Emily G. Niejadlik (ORCID: https://orcid.org/0009-0007-2597-0619)
- Tyler Meeks (ORCID: https://orcid.org/0009-0009-9172-8200)
- Jonathan D Webber
- Hadrien Lehman
- Veronica E. Minster
- Malcolm A. Martin
- Barbara Ann C. Grace
Institutions
- National Institutes of Health (US)
- National Institute of Allergy and Infectious Diseases (US)
- Rockefeller University (US)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1073/pnas.2632384123
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- amfAR, The Foundation for AIDS Research
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research